-
111.发明申请公开(公告)号：US20170304399A1
公开(公告)日：2017-10-26
申请号：US15636486
申请日：2017-06-28
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Jens FRITSCHE , Toni Weinschenk , Steffen Walter , Peter Lewandrowski , Harpreet Singh
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
112.发明申请公开(公告)号：US20170253633A1
公开(公告)日：2017-09-07
申请号：US15445461
申请日：2017-02-28
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K7/08 , C07K16/18 , G01N33/68 , A61K35/17 , A61K39/00 , C12N15/115 , C07K7/06 , C07K14/725
CPC classification number: C07K7/08 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/80 , A61K2039/804 , A61K2039/812 , A61K2039/82 , A61K2039/828 , A61K2039/836 , A61K2039/844 , A61K2039/852 , A61K2039/86 , A61K2039/868 , A61K2039/876 , A61K2039/884 , A61K2039/892 , C07K7/06 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K2319/00 , C12N15/115 , C12N2310/16 , G01N33/6893 , G01N2800/52
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
113.发明申请公开(公告)号：US20170165337A1
公开(公告)日：2017-06-15
申请号：US15374054
申请日：2016-12-09
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C12N5/0783 , C07K16/30 , C07K14/725 , C12N15/115 , C07K7/06 , C07K14/47
CPC classification number: A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K16/30 , C07K2317/34 , C12N5/0636 , C12N15/115 , C12N2310/16
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
114.发明申请公开(公告)号：US20170080070A1
公开(公告)日：2017-03-23
申请号：US15357757
申请日：2016-11-21
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sara KUTSCHER
IPC: A61K39/00 , C12N15/115 , C07K16/18 , C07K14/725 , C07K14/435 , C07K14/74
CPC classification number: A61K39/0011 , A61K35/17 , A61K38/04 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C07K2317/70 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2501/998 , G01N33/6803
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.
-
115.发明申请公开(公告)号：US20170037107A1
公开(公告)日：2017-02-09
申请号：US15199244
申请日：2016-06-30
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Helen HOERZER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/705 , A61K39/00 , C12N5/0783 , C07K16/28 , C07K16/30 , C07K14/74 , C07K14/725 , C12N15/115
CPC classification number: C07K14/4748 , A61K35/17 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2035/124 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , C12Q2600/158 , G01N33/56977 , G01N33/57449 , G01N33/57492 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
116.发明申请公开(公告)号：US20170037093A1
公开(公告)日：2017-02-09
申请号：US15199338
申请日：2016-06-30
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Helen HOERZER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K39/00 , C07K14/74 , C07K14/725
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20160289296A1
公开(公告)日：2016-10-06
申请号：US15082920
申请日：2016-03-28
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Colette SONG
CPC classification number: A61K39/0011 , A61K35/17 , A61K2035/124 , A61K2039/505 , A61K2039/5158 , A61K2039/572 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/18 , C07K16/2833 , C07K16/3038 , C07K2317/73 , C07K2317/76 , C07K2319/33 , C07K2319/55 , C12N5/0636 , C12N15/115 , C12N2310/16 , G06F19/20
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
118.发明申请NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER 有权对包括胃肠癌和胃癌的几种肿瘤的新型免疫治疗公开(公告)号：US20150147347A1
公开(公告)日：2015-05-28
申请号：US14615539
申请日：2015-02-06
Applicant: immatics biotechnologies GmbH
Inventor： Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH
CPC classification number: A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽的组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的95种新型肽序列及其衍生自人类肿瘤细胞HLA I类分子的变体。
-
公开(公告)号：US20250163124A1
公开(公告)日：2025-05-22
申请号：US19024104
申请日：2025-01-16
Applicant: Immatics Biotechnologies GmbH
Inventor： Sebastian BUNK , Dominik MAURER , Jens FRITSCHE , Claudia WAGNER , Leonie ALTEN , Franziska HOFFGAARD , Mathias FERBER
IPC: C07K14/725 , A61K35/17 , C12N5/0783 , C12N15/09
Abstract: The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.
-
公开(公告)号：US20240366669A1
公开(公告)日：2024-11-07
申请号：US18599849
申请日：2024-03-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Ricarda HANNEN , Jens HUKELMANN , Florian KOEHLER , Daniel Johannes KOWALEWSKI , Heiko SCHUSTER , Oliver SCHOOR , Michael ROEMER , Chih-Chiang TSOU , Jens FRITSCHE
IPC: A61K35/17 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/0783
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
645
records
(took 0.062 seconds)
